What was corrected and how
A subsequent correction by the company to the contents of an already published filing.
Full-year earnings forecast for the fiscal year ending December 2026
Net Sales ¥3,356 million / Operating profit ¥660 million / Ordinary income ¥651 million / Net income for the current fiscal year ¥428 million / Dividends ¥50.56
Net Sales ¥5,656 million / Operating profit ¥740 million / Ordinary income ¥730 million / Net income for the current fiscal year ¥440 million / Dividends ¥52.12
Impact of consolidation starting in the fourth quarter of the fiscal year ending December 2026. The full-year earnings forecast for the fiscal year ending December 2026 has been revised upward.
This revision is due to the increase in consolidated subsidiaries resulting from the acquisition of shares in GMO NIKKO and GMO Insight. Ordinary profit reflects interest expenses and other costs associated with the borrowings.
| Item | Details |
|---|---|
| Location of correction | Full-year earnings forecast for the fiscal year ending December 2026 |
| Details of correction | Net Sales ¥3,356 million / Operating profit ¥660 million / Ordinary income ¥651 million / Net income for the current fiscal year ¥428 million / Dividends ¥50.56 → Net Sales ¥5,656 million / Operating profit ¥740 million / Ordinary income ¥730 million / Net income for the current fiscal year ¥440 million / Dividends ¥52.12（Net Sales +68.5％ / Operating profit +12.1％ / Ordinary income +12.1％ / Net income for the current fiscal year +2.8％ / Dividends +3.1％） |
| Reason for correction | This revision is due to the increase in consolidated subsidiaries resulting from the acquisition of shares in GMO NIKKO and GMO Insight. Ordinary profit reflects interest expenses and other costs associated with the borrowings. |
| Impact on Business Performance | Impact of consolidation starting in the fourth quarter of the fiscal year ending December 2026. The full-year earnings forecast for the fiscal year ending December 2026 has been revised upward. |
Items this document does not state (2)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.This is due to the increase in consolidated subsidiaries resulting from the acquisition of shares in GMO NIKKO and GMO Insight. Ordinary profit reflects interest expenses and other costs associated with the borrowings.